The Evolving Spectrum of Pediatric Non-Type 1 Diabetes: A Clinical and Genetic Study
This retrospective study of 82 pediatric patients at a tertiary center reveals that Type 2 diabetes and MODY are the predominant forms of non-type 1 diabetes, with BMI and endogenous insulin levels serving as key differentiators while HbA1c at diagnosis fails to distinguish between these major subtypes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a child develops high blood sugar, the medical world has traditionally sorted the cause into two main buckets. The first is type 1 diabetes, where the body's immune system mistakenly attacks the cells that make insulin, a hormone needed to process sugar. The second is type 2 diabetes, often linked to excess weight, where the body becomes resistant to its own insulin. For decades, doctors assumed that if a child did not fit the classic picture of type 1, they likely had type 2. However, a growing body of evidence suggests this binary view is too simple. There is a third category, a group of conditions caused by specific errors in a person's genetic code rather than lifestyle or immune attacks. These genetic forms, which include a type called maturity-onset diabetes of the young, or MODY, can look very similar to the common types on the surface but require completely different treatments. Understanding which bucket a child truly belongs to is critical, because giving the wrong medication can be ineffective or even harmful, while the right genetic diagnosis can unlock a simpler, more targeted path to health.
In a large medical center in Turkey, a team of researchers set out to map the landscape of these non-type 1 diabetes cases in children and teenagers. They looked back at the records of 82 young patients, all under the age of 18, who had been diagnosed with diabetes that was not type 1 between the years 2011 and 2026. The goal was to see what these children actually had, how their bodies differed, and whether the types of diabetes they carried were changing over time. The team found that the group was split almost evenly between the two most common non-type 1 forms. Just over half of the patients, 38 children, had type 2 diabetes. Almost as many, 36 children, had MODY. The remaining eight patients had other rare forms, including syndromic diabetes where the condition is part of a larger genetic disorder, or secondary diabetes caused by other medical issues.
The researchers discovered that while these children all shared high blood sugar, their bodies told very different stories. The children with type 2 diabetes were significantly heavier than the others, with body mass measurements that were much higher than average for their age and height. Their bodies were also producing large amounts of insulin and C-peptide, a substance that acts as a marker for how much insulin the pancreas is making. This high output suggests their bodies were struggling to use the insulin effectively. In contrast, the children with MODY had much lower levels of insulin and C-peptide. Their bodies were not resisting insulin as much; instead, their genetic instructions for making insulin were simply weaker or broken. This difference in how the body handles insulin turned out to be a more reliable clue for telling the two groups apart than the severity of their high blood sugar at the moment of diagnosis.
One of the most striking findings was that the severity of the disease at the start did not predict the cause. The researchers grouped the children by how high their blood sugar was when they were first tested, ranging from mild to severe. They found that children with mild, moderate, and severe high blood sugar were all found in both the type 2 and MODY groups. A child with very high blood sugar could have a genetic form, while a child with barely elevated levels could have type 2. This means that looking at a single blood sugar number is not enough to know what is wrong. The team also noted that the number of children being diagnosed with type 2 diabetes grew steadily over the fifteen-year study period, rising from just three cases in the early years to twenty-three in the final years, mirroring a broader global trend of increasing childhood obesity.
For the children with MODY, the researchers went a step further and looked at their DNA. They found that 31 of the 36 children suspected of having this genetic condition actually had a confirmed genetic error. The team identified eight different genes responsible for the problem. The most common errors were found in four specific genes, which accounted for the vast majority of these cases. This high rate of confirmation suggests that when a child presents with a family history of diabetes but does not fit the typical pattern of type 1 or type 2, testing their genes is a powerful tool. It is worth noting that some children in the study, even those with confirmed genetic forms, had markers in their blood that usually indicate an immune attack, a finding that challenges the old rule that such markers automatically rule out a genetic cause.
The study concludes that the world of pediatric diabetes is far more diverse than previously thought. In this specialized hospital setting, type 2 diabetes and genetic MODY were the dominant forms of non-type 1 diabetes, appearing in nearly equal numbers. The researchers emphasize that while a child's weight and insulin levels can offer helpful hints, they are not the final answer. The only way to be certain is to look at the whole picture: the family history, the body's weight, the insulin levels, and, when the clues point that way, the genetic code itself. By sorting these children correctly, doctors can move away from a one-size-fits-all approach and provide treatments that match the specific biological cause of the disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.